Public Advisory - TUMS Peppermint Regular Strength tablets: One lot recalled due to contamination
OTTAWA, ON, Nov. 30, 2022 /CNW/ - Summary
Product: TUMS Peppermint Regular Strength tablets, packages of three rolls of 12 tablets, lot HA7H, NPN 01970240
Issue: Health product ? contamination, product safety
What to do: Stop using the recalled product. Speak to a health care professional if you have taken this product and have health concerns.
Affected products
Product
NPN
Lot
Expiry
TUMS Peppermint Regular Strength (500mg) tablets, packages of three rolls of 12 tablets
01970240
HA7H
August 2027
Issue
GlaxoSmithKline Consumer Healthcare ULC is recalling one lot of TUMS Peppermint Regular Strength tablets after some tablets were found to contain fragments of fibreglass and other material, including paper and aluminum foil. The product is sold in a package of three rolls containing 12 tablets each, and was distributed across Canada starting on October 25, 2022.
TUMS is an antacid indicated for adult use to relieve indigestion and heartburn caused by too much acid in the stomach.
If consumed, the fragments should pass through most people's digestive systems with no concern; however, elderly people and people who have narrow areas in their intestines because of disease or surgery may be at risk of injury.
Health Canada is monitoring the company's recall and will update the public if any new health risks are identified.
What you should do
Stop using the recalled product. Contact your health care practitioner if you have used this product and have concerns about your health.
Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste; or
Return the product to your local pharmacy for proper disposal
Contact GSK Consumer Healthcare (doing business as Haleon) by calling 1-905-507-7000, or by emailing [email protected], if you have questions about this recall.
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...